The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease

ISSN： 1466-1861

Source： Mediators of Inflammation, Vol.7, Iss.3, 1998-06, pp. : 137-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

By Pasternak Björn Svanström Henrik Schmiegelow Kjeld Jess Tine Hviid Anders

American Journal of Epidemiology, Vol. 177, Iss. 11, 2013-06 ,pp. : 1296-1305

Oxford University Press

Access to resources Recommend Favorite

Regenerative medicine: prospects for the treatment of inflammatory bowel disease

By Almeida-Porada Graça Soland Melisa Boura Joana Porada Christopher D

Regenerative Medicine, Vol. 8, Iss. 5, 2013-09 ,pp. : 631-644

Future Medicine

Access to resources Recommend Favorite

Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 97, Iss. 1, 2015-01 ,pp. : 22-28

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

By Mulder C. J. J. Hazel S. J. Van Den

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite

Cytokines in inflammatory bowel disease

By Beck P. L. Wallace J. L.

Mediators of Inflammation, Vol. 6, Iss. 2, 1997-04 ,pp. : 95-103

Informa Healthcare

Access to resources Recommend Favorite